Li et al. found that alanine aminotransferase (ALT) normalization rate, HBV-DNA and HBeAg negative conversion rate and anti-HBe seroconversion rate of the treatment group was treated with baicalin and telbivudine were significantly higher than the control group were treated with only telbivudine, and that post-treatment markers of hepatic fibrosis, hyaluronic acid, laminin, and type III procollagen, in the treatment group differed significantly from those in the control group (Li et al., 2011). This evidence concerns the gene LAMB2 and Hepatic fibrosis.